Nitiyanant W, Sriussadaporn S, Deerochanawong C, Ngawngamrat S, Benjasuratwong Y, Patanaungkul S
Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
J Med Assoc Thai. 1997 Dec;80(12):771-7.
This study was aimed to evaluate the efficacy and safety of gliquidone, the latest available sulphonylurea, as a monotherapy for patients with non-insulin dependent diabetes millitus (NIDDM). Ninety patients attending diabetic clinics of Siriraj, Rajavithi and Pramongkutklao Army Hospitals were recruited in study. They were 21 males and 69 females, 27-82 years old (mean +/- SD = 52.3 +/- 11.2 years). The diabetic duration varied from newly diagnosed to 18 years (mean +/- SD = 1.5 +/- 2.8 years). Four weeks washout period was applied to 40 patients who had been treated with oral hypoglycemic agents. Before initiation of therapy, fasting venous blood samples were obtained for determination of fasting plasma glucose (FPG), Hemoglobin A1 (HbA1), lipid profile, chemistry profile and complete blood count (CBC). The starting dose of gliquidone was 15-60 mg by mouth once or twice daily. The dosage was adjusted every 4 weeks. FPG, HbA1 and lipid profile were assessed every 4 weeks. Blood chemistry profile and CBC were monitored at 4 weeks after treatment and at the end. After 12 weeks of therapy, FPG and HbA1 significantly declined from 220.8 +/- 55.5 mg/dl and 11.3 +/- 2.6 per cent to 159.1 +/- 38.6 mg/dl and 9.2 +/- 1.4 per cent, respectively (p < 0.001). A small but statistically significant decrease in serum total cholesterol from 229.3 +/- 46.9 to 219.8 +/- 40.7 mg/dl (p < 0.01) as well as serum low density lipoprotein cholesterol from 150.2 +/- 43.7 to 142.2 +/- 42.1 mg/dl (p < 0.05) were observed. Serum triglyceride and high density lipoprotein cholesterol did not significantly alter. Clinical follow-up, blood chemistry profile and CBC did not indicate any adverse reactions from gliquidone therapy. We concluded that gliquidone is an effective oral hypoglycemic agent for treating patients with NIDDM. Adverse effects were not experienced by this group of patients.
本研究旨在评估最新可用的磺脲类药物格列喹酮作为非胰岛素依赖型糖尿病（NIDDM）患者单一疗法的疗效和安全性。招募了90名在诗里拉吉医院、拉贾维提医院和普拉蒙库特考陆军医院糖尿病诊所就诊的患者。他们中男性21名，女性69名，年龄在27至82岁之间（平均±标准差=52.3±11.2岁）。糖尿病病程从新诊断到18年不等（平均±标准差=1.5±2.8年）。对40名曾接受口服降糖药治疗的患者进行了为期4周的洗脱期。在开始治疗前，采集空腹静脉血样以测定空腹血糖（FPG）、糖化血红蛋白A1（HbA1）、血脂谱、生化指标和全血细胞计数（CBC）。格列喹酮的起始剂量为口服15 - 60毫克，每日一次或两次。每4周调整一次剂量。每4周评估一次FPG、HbA1和血脂谱。在治疗4周后及结束时监测血液生化指标和CBC。治疗12周后，FPG和HbA1分别从220.8±55.5毫克/分升和11.3±2.6%显著降至159.1±38.6毫克/分升和9.2±1.4%（p<0.001）。观察到血清总胆固醇从229.3±46.9降至219.8±40.7毫克/分升有小幅但具有统计学意义的下降（p<0.01），血清低密度脂蛋白胆固醇从150.2±43.7降至142.2±42.1毫克/分升（p<0.05）。血清甘油三酯和高密度脂蛋白胆固醇没有显著变化。临床随访、血液生化指标和CBC未显示格列喹酮治疗有任何不良反应。我们得出结论，格列喹酮是治疗NIDDM患者的一种有效口服降糖药。该组患者未出现不良反应。
